At a Glance
- Company: Eli Lilly
- Targets: Curevo, LimmaTech Biologics, Vaccine Company
- Deal value: Up to $3.8 billion
- Focus area: Vaccines and infectious diseases
- Next steps: Integrate assets and advance clinical programmes
What happened?
Eli Lilly has agreed to acquire three vaccine-focused biotech companies—Curevo, LimmaTech Biologics and Vaccine Company—in a package deal worth up to $3.8 billion. The move significantly expands Lilly’s presence in vaccines and infectious diseases.
Why does it matter?
Lilly has traditionally focused on areas such as diabetes, oncology and immunology, so this marks a broader strategic push into infectious disease prevention. Vaccines remain a high-impact area with growing commercial and public health importance, particularly after the COVID-19 pandemic.
Who’s behind it?
Eli Lilly is a major US pharmaceutical company seeking to diversify its pipeline. The acquired companies bring complementary vaccine technologies and programmes targeting bacterial and viral diseases.
How was it achieved?
The combined deal structure includes upfront payments and milestone-based components tied to development and commercial progress. Each company contributes different vaccine platforms and assets, allowing Lilly to build a more diversified infectious disease portfolio in a single transaction.
What’s next?
Lilly will integrate the acquired programmes into its R&D organisation and advance them through clinical development. The company is expected to prioritise candidates with near-term clinical milestones while continuing to build out its vaccine capabilities.